| Christopher Ballantyne, MD | |
|
13400 E Shea Blvd # 800719, Scottsdale, AZ 85259-5499 | |
| (480) 301-8000 | |
| Not Available |
| Full Name | Christopher Ballantyne |
|---|---|
| Gender | Male |
| Speciality | Urology |
| Location | 13400 E Shea Blvd # 800719, Scottsdale, Arizona |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700317906 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208800000X | Urology | 70160 (Arizona) | Primary |
| Entity Name | Mayo Clinic Arizona |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1558332494 PECOS PAC ID: 7012829930 Enrollment ID: O20031105000782 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a new regulator of the innate immune response—the immediate, natural immune response to foreign invaders.
Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular changes and how they influence the progression and severity of glaucoma, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute turned to a mouse model of the disease.
Data from a long-term open-label extension study from the first Phase 3 Fampridine-SR trial, known as MS-F203, showed that 24.9% of extension study participants with multiple sclerosis (MS) met the criteria as Extension Timed Walk Responders (ETWRs) after one year of treatment and demonstrated improved walking speed over a two year period.
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
Inviragen, Inc. today announced the initiation of a Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Christopher Ballantyne, MD 13400 E Shea Blvd # 800719, Scottsdale, AZ 85259-5499 Ph: (480) 301-8000 | Christopher Ballantyne, MD 13400 E Shea Blvd # 800719, Scottsdale, AZ 85259-5499 Ph: (480) 301-8000 |
News Archive
Scientists at Sanford Burnham Prebys Medical Discovery Institute have identified a new regulator of the innate immune response—the immediate, natural immune response to foreign invaders.
Glaucoma, the second leading cause of blindness, usually stems from elevated eye pressure, which in turn damages and destroys specialized neurons in the eye known as retinal ganglion cells. To better understand these cellular changes and how they influence the progression and severity of glaucoma, researchers at University of California, San Diego School of Medicine and Shiley Eye Institute turned to a mouse model of the disease.
Data from a long-term open-label extension study from the first Phase 3 Fampridine-SR trial, known as MS-F203, showed that 24.9% of extension study participants with multiple sclerosis (MS) met the criteria as Extension Timed Walk Responders (ETWRs) after one year of treatment and demonstrated improved walking speed over a two year period.
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine today announces a strategic collaboration with Actelion Pharmaceuticals Ltd, one of the Janssen Pharmaceutical Companies of Johnson & Johnson and a global leader in pulmonary arterial hypertension, to discover and validate a breath-based test to help facilitate the early diagnosis of pulmonary hypertension and its subtypes.
Inviragen, Inc. today announced the initiation of a Phase 2, randomized, double-blind, placebo-controlled study of DENVax, the Company's investigational dengue vaccine.
› Verified 3 days ago
Dr. Daniel Mark Frendl, MD, PHD Urology Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Dr. Micheal F. Darson, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 17300 N Perimeter Dr Ste 220, Scottsdale, AZ 85255 Phone: 480-661-2662 Fax: 480-661-9716 | |
Logan Garrett Briggs, MD Urology Medicare: Medicare Enrolled Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Erik Edwin Alexander, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 10301 N 92nd St, Suite 101, Scottsdale, AZ 85258 Phone: 480-661-2662 Fax: 480-661-9716 | |
Dr. Kelli Xenia Gross, M.D. Urology Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Dr. Aqsa Khan, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 13400 E Shea Blvd, Scottsdale, AZ 85259 Phone: 480-301-8000 | |
Bernard Michael Gburek, MD Urology Medicare: Accepting Medicare Assignments Practice Location: 20401 N 73rd St Ste 105, Scottsdale, AZ 85255 Phone: 480-661-2662 Fax: 480-307-9327 |